Wockhardt has reported results for fourth quarter and year ended March 31, 2019.
The company has reported a net loss of Rs 33.52 crore for the quarter ended March 31, 2019 against net profit of Rs 172.44 crore for the same quarter in the previous year. Total income of the company decreased around 48.50% to Rs 475.79 crore for quarter under review as compared to Rs 923.90 crore for the quarter ended March 31, 2018.
On consolidated basis, the company has reported a net loss of 13.90 crore for the quarter ended March 31, 2019 as compared to a net loss of Rs 152.91 crore for the corresponding quarter in the FY18. Total consolidated income of the company decreased by 2.50% at Rs 984.55 crore for quarter under review as compared to Rs 1,009.85 crore for the same quarter ended previous year.
For the year ended March 31, 2019, the company has posted a net loss of Rs 81.89 crore against net profit of Rs 68.66 crore for the previous year. Total income of company decreased by 13.93% at Rs 2,180.95 crore for year under review as compared to Rs 2,534.14 crore for year ended March 31, 2018.
For the year ended March 31, 2019, on the consolidated basis, the company has reported a net loss at Rs 216.66 crore as compared to net loss of Rs 666.85 crore for the previous year. However, total income of company increased marginally by 3.01% at Rs 4,179.40 crore for year under review as compared to Rs 4,057.13 crore for year ended March 31, 2018.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1878.00 |
Dr. Reddys Lab | 1373.70 |
Cipla | 1537.55 |
Lupin | 2396.30 |
Zydus Lifesciences | 990.55 |
View more.. |